End-of-Life Treatment With Immunotherapy Increasing for Patients With Cancer

Follow Drugslib on

Medically reviewed by Drugs.com.

By Lori Solomon HealthDay Reporter

THURSDAY, Jan. 11, 2024 -- Initiation of immunotherapy for metastatic cancer at the end of life (EOL) is increasing over time, according to a study published online Jan. 4 in JAMA Oncology.

Daniel M. Kerekes, M.D., from Yale University in New Haven, Connecticut, and colleagues examined patient characteristics, practice patterns, and risk factors concerning EOL-initiated immunotherapy over time. The analysis included data from 242,371 patients with metastatic melanoma, non-small cell lung cancer, or kidney cell carcinoma.

The researchers found that the percentage of patients who received EOL-initiated immunotherapy increased over time for all cancers. In 2019, more than one in 14 immunotherapy treatments were initiated within one month of death. Patients with three or more organs involved in metastatic disease were significantly more likely to die within one month of immunotherapy initiation versus those with lymph node involvement only (adjusted odds ratio, 3.8). Compared with treatment at a nonacademic or very low-volume center, treatment at an academic or high-volume center was associated with lower odds of death within a month of initiating immunotherapy (odds ratios, 0.69 and 0.70, respectively).

"More research on the benefit and value of these therapies in patients with advanced-stage disease is needed," the authors write.

Several authors disclosed ties to industry.

Abstract/Full Text (subscription or payment may be required)

Editorial (subscription or payment may be required)

Disclaimer: Statistical data in medical articles provide general trends and do not pertain to individuals. Individual factors can vary greatly. Always seek personalized medical advice for individual healthcare decisions.

Source: HealthDay

Posted : 2024-01-12 04:15

Read more

Disclaimer

Every effort has been made to ensure that the information provided by Drugslib.com is accurate, up-to-date, and complete, but no guarantee is made to that effect. Drug information contained herein may be time sensitive. Drugslib.com information has been compiled for use by healthcare practitioners and consumers in the United States and therefore Drugslib.com does not warrant that uses outside of the United States are appropriate, unless specifically indicated otherwise. Drugslib.com's drug information does not endorse drugs, diagnose patients or recommend therapy. Drugslib.com's drug information is an informational resource designed to assist licensed healthcare practitioners in caring for their patients and/or to serve consumers viewing this service as a supplement to, and not a substitute for, the expertise, skill, knowledge and judgment of healthcare practitioners.

The absence of a warning for a given drug or drug combination in no way should be construed to indicate that the drug or drug combination is safe, effective or appropriate for any given patient. Drugslib.com does not assume any responsibility for any aspect of healthcare administered with the aid of information Drugslib.com provides. The information contained herein is not intended to cover all possible uses, directions, precautions, warnings, drug interactions, allergic reactions, or adverse effects. If you have questions about the drugs you are taking, check with your doctor, nurse or pharmacist.

Popular Keywords